Literature DB >> 29672292

Identification of Risk Factors in High-Dose Methotrexate-Induced Acute Kidney Injury in Childhood Acute Lymphoblastic Leukemia.

Dao-Hai Cheng1, Hua Lu1, Tao-Tao Liu1, Xiao-Qin Zou2, Hui-Mei Pang1.   

Abstract

AIMS: Although high-dose methotrexate (HDMTX) is an effective means for the treatment of acute lymphoblastic leukemia (ALL), the development of renal dysfunction remains a significant management challenge. This study aimed to identify the key factors in HDMTX-induced acute kidney injury (AKI) in childhood ALL.
METHODS: We retrospectively analyzed the clinical data in 1,329 courses of HDMTX treatment in 336 Chinese ALL children at the First Affiliated Hospital of Guangxi Medical University from September 2012 to November 2016. The clinical data were compared between the groups of children with development of AKI and those without. Risk factors were identified by multiple logistic regression analysis, and the diagnostic performance of plasma MTX concentration was evaluated by receiver operating characteristic (ROC) curve analysis.
RESULTS: AKI was observed in 88 patients (26.2%) and 104 courses (7.8%). Binary logistic regression revealed that age (OR 1.349; p = 0.005), first HDMTX course (OR 1.767; p = 0.013), MTX dose per body surface area (BSA; OR 1.944; p = 0.015), and baseline serum total protein (OR 0.929; p = 0.021) significantly correlated with AKI. The area under the ROC for 48-h plasma MTX concentration was 0.890 (95% CI 0.850-0.930), and sensitivity and specificity values of the cut-off value were 78.8 and 90.4%, respectively.
CONCLUSION: Increasing age, higher MTX dose per BSA, lower baseline serum protein, and first HDMTX course were significant risk factors for developing HDMTX-induced AKI in childhood ALL. The threshold of 48-h MTX plasma concentration is valuable for the prediction of HDMTX-induced AKI.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Acute kidney injury; Acute lymphoblastic leukemia; Children; High-dose methotrexate

Year:  2018        PMID: 29672292     DOI: 10.1159/000486823

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  7 in total

Review 1.  Metabolic underpinnings of leukemia pathology and treatment.

Authors:  Travis Nemkov; Angelo D'Alessandro; Julie A Reisz
Journal:  Cancer Rep (Hoboken)       Date:  2018-10-07

2.  Development and Validation of UHPLC-MS/MS Assay for Therapeutic Drug Monitoring of High-dose Methotrexate in Children with Acute Lymphoblastic Leukemia.

Authors:  Le-Jing Lian; Bin Lin; Xiao Cui; Jie He; Zhe Wang; Xiao-Dong Lin; Wei-Jian Ye; Rui-Jie Chen; Wei Sun
Journal:  Drug Des Devel Ther       Date:  2020-11-10       Impact factor: 4.162

3.  Novel risk factors for glucarpidase use in pediatric acute lymphoblastic leukemia: Hispanic ethnicity, age, and the ABCC4 gene.

Authors:  Mark C Zobeck; M Brooke Bernhardt; Kala Y Kamdar; Karen R Rabin; Philip J Lupo; Michael E Scheurer
Journal:  Pediatr Blood Cancer       Date:  2021-03-31       Impact factor: 3.167

4.  A Case of Methotrexate Neurotoxicity Presented as Status Epilepticus, Encephalopathy, and High Fever.

Authors:  Itay Ayalon; Shirley Friedman; Yoav Binenbaum; Noga Oppenheimer; Shelly Shiran; Galia Grisaru-Soen; Shimrit Uliel-Sibony; Miguel Glatstein; Jennifer Melissa Kaplan; Efraim Sadot
Journal:  J Investig Med High Impact Case Rep       Date:  2019 Jan-Dec

5.  A challenging case of an adolescent and young adult patient with high-risk acute lymphoblastic leukemia: the need for a multidisciplinary approach: a case report.

Authors:  Izabela Kranjčec; Nuša Matijašić; Slaven Abdović; Iva Hižar Gašpar; Lavinia La Grasta Sabolić; Filip Jadrijević-Cvrlje
Journal:  J Med Case Rep       Date:  2022-04-11

6.  Detection of pediatric drug-induced kidney injury signals using a hospital electronic medical record database.

Authors:  Yuncui Yu; Xiaolu Nie; Yiming Zhao; Wang Cao; Yuefeng Xie; Xiaoxia Peng; Xiaoling Wang
Journal:  Front Pharmacol       Date:  2022-09-23       Impact factor: 5.988

7.  Standardized Supportive Care Documentation Improves Safety of High-Dose Methotrexate Treatment.

Authors:  Winfried H Alsdorf; Panagiotis Karagiannis; Claudia Langebrake; Carsten Bokemeyer; Christian Frenzel
Journal:  Oncologist       Date:  2020-11-28       Impact factor: 5.837

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.